Completed PHASE4 INTERVENTIONAL 1-arm NCT02016261

Study to Evaluate Cognitive Functioning in Remitted Depression During Treatment With Fluvoxamine

Open Label, Non-comparative Study to Evaluate Cognitive Functioning in Remitted Depression Outpatients During Long-term Preventive Treatment With Fluvoxamine

Sponsor: Abbott

Conditions Recurrent Depressive Disorder

Interventions Fluvoxamine

Updated 6 times since 2017 Last updated: Jul 20, 2015 Started: Dec 31, 2013 Primary completion: Jul 31, 2015 Completion: Jul 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Recurrent Depressive Disorder and is currently completed. Abbott leads this study, which shows 6 recorded versions since 2013 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Dec 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Abbott
Moscow Research Institute of Psychiatry

Data source: Moscow Research Institute of Psychiatry

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Moscow, Russia